Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Conditions
Keywords
Lymphoma, non-hodgkins lymphoma, Hodgkin's lymphoma, Hodgkin's disease, stem cell transplant, High-risk diffuse large B cell, Transformed low grade lymphoma, T-cell non-Hodgkin's lymphoma, Mantle cell lymphoma at any time in therapy, Double-hit lymphoma
Brief summary
Relapse remains a principle cause of treatment failure for patients with aggressive lymphoma after autologous transplantation. Non-myeloablative allogeneic transplantation allows patients to receive an infusion of donor cells in an attempt to induce a graft versus lymphoma effect. This study will assess the feasibility, safety and efficacy of the combination of autologous stem cell transplantation followed by non-myeloablative transplantation for patients with poor-risk aggressive lymphoma.
Detailed description
This is a phase II clinical trial investigating the feasibility, and efficacy of sequential autologous stem cell transplant followed by non-myeloablative allogeneic transplant for patients with poor risk lymphoma. Patients will be enrolled onto the trial when eligible and undergo standard high-dose chemotherapy with the combination with busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplant. After recovery of counts and clinical status, patients will then proceed to non-myeloablative allogeneic stem cell transplant using a fully matched related or unrelated donor.
Interventions
DRUGBusulfan (conditioning for AUTO transplant)
0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
DRUGEtoposide (conditioning for AUTO transplant)
Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
DRUGCyclophosphamide (conditioning for AUTO transplant)
Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
DRUGMesna (prior to AUTO transplant)
Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
OTHERautologous (auto) peripheral blood stem cell transplantation
Infusion of autologous peripheral blood stem cells on Day 0.
DRUGNeupogen
Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
DRUGFludarabine (conditioning for ALLO Transplant)
Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
OTHERnon-myeloablative allogeneic (allo) transplant
Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10\^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10\^6/kg of recipient's actual body weight
DRUGTacrolimus
Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
DRUGSirolimus
Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
DRUGMethotrexate
Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
Sponsors
Dana-Farber Cancer Institute
Massachusetts General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients with high-risk diffuse large B cell or transformed low grade lymphoma defined as: * Residual disease after at least 6 cycles of anthracycline-based chemotherapy (with residual disease defined as persistent bone marrow involvement and/or persistent measurable lymph node or solid organ masses that are PET or gallium avid) * Progressive disease after at least 2 cycles of anthracycline-based chemotherapy * Patients with an initial complete response but subsequent relapse within 6 months after completion of anthracycline-based chemotherapy * Patients with any T-cell non-Hodgkin's lymphoma as defined as: * Peripheral T-cell lymphoma (ALK negative PTCL-U) including PTCL-NOS, HSGD (hepato-splenic gamma-delta TCL), AITL (angioimmunoblastic T-cell lymphoma), EATL (enteropathy associated T-cell lymphoma), ALK-negative anaplastic large cell lymphoma * Any T-cell histology (except LGL) with residual disease after at least 4 cycles of anthracycline-based chemotherapy (with residual disease defined as persistent bone marrow involvement and/or persistent measurable lymph node or solid organ masses that are PET or gallium avid) * Patients with mantle cell lymphoma at any time in therapy * Patients with double-hit lymphoma as characterized by the presence of concurrent overexpression of Bcl-2 and c-myc * Patients with Hodgkin's lymphoma that is * Refractory to first-line therapy and at least one second line chemotherapy regimen * Relapsed Hodgkin's lymphoma which is refractory to at least one salvage chemotherapy regimen. * Patients with CLL/SLL with 17p- cytogenetic abnormality * Age 18 years and greater * ECOG performance status 0-2 * Ability to understand and the willingness to sign a written informed consent document. * Responsive disease to last therapy as determined by at least one of the following: * At least PR by Revised Response Criteria * At least PR by traditional Cheson Criteria * \< 10% of overall cellularity involved with disease on bone marrow biopsy for patients with involvement of the bone marrow * Minimum of 2 x 106 CD34+ cells / kg already collected and frozen. These stem cells may have been collected from PBSC pheresis, bone marrow harvest, or the combination.
Exclusion criteria
Patients will be re-evaluated after autologous transplant prior to proceeding to non-myeloablative transplant * Pregnancy * Evidence of HIV infection * Heart failure uncontrolled by medications or ejection fraction less than 45% * Active involvement of the CNS by lymphoma * Inability to provide informed consent * Previous autologous or allogeneic stem cell transplant * Creatinine greater than 2 gm/dL or 24 hour urine creatinine clearance \< 50 cc/minute (does not have to satisfy both) * Total bilirubin greater than 2 times the upper limit of normal except when due to Gilbert's syndrome or hemolysis. * Transaminases greater than 3 times the upper limit of normal * FVC or DLCO of less than 50% of predicted (DLCO corrected for hemoglobin level) * Already known to not possess suitably HLA-matched related or unrelated donor Eligibility to proceed to allogeneic transplant Cannot be admitted for allogeneic transplant earlier than 40 days and no later than 180 days after autologous stem cell transplant. * HLA identical (A, B, C and DR) related or unrelated donor available. HLA typing of class I loci (HLA- A, B, C) will be based on complement dependent cytotoxicity assay or PCR of sequence specific oligonucleotide primers (SSOP). Typing of HLA class II (DRB1) will be based on PCR of sequence specific oligonucleotide primers (SSOP). * No need for intravenous hydration in the previous 2 weeks * Resolved mucositis * Renal, cardiac, pulmonary, and hepatic function meet standard criteria for nonmyeloablative SCT as listed below: * Serum Cr \< 2 gm/dL * LV ejection fraction \> 30% and no uncontrolled symptoms of congestive heart failure * DLCO \> 50% of predicted value (corrected for hemoglobin) * Transaminases \< 5X the institution upper limit of normal * Bilirubin \< 3X the institution upper limit of normal except when Gilbert's Syndrome or hemolysis is present * ECOG PS ≤ 2 * No intravenous antimicrobials within 2 weeks * No evidence of progressive disease, defined as a 25% increase from nadir in the sum of the product of the diameters (SPD) of any lymph node previously identified as abnormal prior to autologous transplant or the appearance of any new lymph node greater than 1.5 cm in greatest diameter, new bone marrow involvement, or new solid organ nodule greater than 1 cm in diameter. This restaging study will be performed at least 28 days after the autologous transplant and within 60 days prior to admission for allogeneic transplant. Status of stable disease (SD) is acceptable to proceed to allogeneic transplant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peripheral Blood All-cell Donor Chimerism | 100 days post allogeneic transplant | Successful donor stem cell engraftment is defined as when ≥ 80% of hematopoietic elements are donor-derived as determined by chimerism assays from peripheral blood at day 100 after non-myeloablative allogeneic stem cell transplantation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD) | within 200 days after allogeneic transplant | Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening. |
| Cumulative Incidence of Extensive Chronic Graft-versus-host-disease | 1-year after allogeneic transplant | Extensive chronic graft versus-host-disease (GVHD) was defined as GVHD that required systemic immunosuppression. |
| Cumulative Incidence of Non-relapse Mortality | 2-years after allogeneic transplant | Non-relapse mortality is defined as participants who die from causes other than their underlying disease relapse, such as infection or graft versus host disease |
| Cumulative Incidence of Disease Relapse | 2-years after allogeneic transplant | — |
| Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants | 2 years after allogeneic transplant | — |
| Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL | within 28 days after allogeneic transplant | — |
| Estimated Two Year Progression Free Survival Rate for All Participants | 2 years | — |
| Estimated Two Year Overall Survival Rate for All Participants | 2 years | — |
| Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant | Two Years | — |
| Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant | two years | — |
| Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants | Two-years after Allogeneic Transplant | — |
Countries
United States
Participant flow
Recruitment details
Participants were enrolled between October 2010 and June 2013.
Participants by arm
| Arm | Count |
|---|---|
| Autologous Then Allogeneic Transplant Autologous then allogeneic stem cell transplantation | 42 |
| Total | 42 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Evaluation for Allogeneic Transplant | Lack of Efficacy | 6 |
| Evaluation for Allogeneic Transplant | No suitable donor | 2 |
| Evaluation for Allogeneic Transplant | therapy-related AML diagnosed | 1 |
| Evaluation for Allogeneic Transplant | Withdrawal by Subject | 4 |
Baseline characteristics
| Characteristic | Autologous Then Allogeneic Transplant |
|---|---|
| Age, Continuous | 56.5 years |
| Diagnosis Double-Expressing Non-Hodgkin Lymphoma | 9 Participants |
| Diagnosis Heavy chain disease | 1 Participants |
| Diagnosis Mantle cell Non-Hodgkin Lymphoma | 3 Participants |
| Diagnosis Relapsed/refractory Diffuse Large B-cell Lymphoma | 10 Participants |
| Diagnosis Relapsed/Refractory Hodgkin Lymphoma | 1 Participants |
| Diagnosis Relapsed/refractory Non-Hodgkin Lymphoma | 6 Participants |
| Diagnosis T-cell Non-Hodgkin Lymphoma | 4 Participants |
| Diagnosis Transformed B-cell Non-Hodgkin Lymphoma | 8 Participants |
| Disease status at study entry Complete Response | 21 Participants |
| Disease status at study entry Partial Response | 21 Participants |
| Prior lines of chemotherapy | 2 lines |
| Region of Enrollment United States | 42 Participants |
| Sex: Female, Male Female | 16 Participants |
| Sex: Female, Male Male | 26 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 24 / 42 |
| serious Total, serious adverse events | 5 / 42 |
Outcome results
Primary
Peripheral Blood All-cell Donor Chimerism
Successful donor stem cell engraftment is defined as when ≥ 80% of hematopoietic elements are donor-derived as determined by chimerism assays from peripheral blood at day 100 after non-myeloablative allogeneic stem cell transplantation.
Time frame: 100 days post allogeneic transplant
Population: Participants who underwent the full tandem AUTO-ALLO stem cell transplant
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Peripheral Blood All-cell Donor Chimerism | 95 percentage of donor-derived elements |
Secondary
Cumulative Incidence of Disease Relapse
Time frame: 2-years after allogeneic transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Cumulative Incidence of Disease Relapse | 17.2 percentage of participants |
Secondary
Cumulative Incidence of Extensive Chronic Graft-versus-host-disease
Extensive chronic graft versus-host-disease (GVHD) was defined as GVHD that required systemic immunosuppression.
Time frame: 1-year after allogeneic transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Cumulative Incidence of Extensive Chronic Graft-versus-host-disease | 37.9 percentage of participants |
Secondary
Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD)
Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening.
Time frame: within 200 days after allogeneic transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Cumulative Incidence of Grades II to IV Acute Graft Versus Host Disease (GVHD) | 13.8 percentage of participants |
Secondary
Cumulative Incidence of Non-relapse Mortality
Non-relapse mortality is defined as participants who die from causes other than their underlying disease relapse, such as infection or graft versus host disease
Time frame: 2-years after allogeneic transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Cumulative Incidence of Non-relapse Mortality | 11.1 percentage of participants |
Secondary
Estimated Two Year Overall Survival Rate for All Participants
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Estimated Two Year Overall Survival Rate for All Participants | 83 percentage of participants |
Secondary
Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants
Time frame: Two-years after Allogeneic Transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Estimated Two Year Overall Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants | 89 percentage of participants |
Secondary
Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant
Time frame: two years
Population: Participants who ONLY underwent Autologous transplant, did not proceed to Allogeneic transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Estimated Two Year Overall Survival Rate for Participants Undergoing Only Autologous Transplant | 69 percentage of participants |
Secondary
Estimated Two Year Progression Free Survival Rate for All Participants
Time frame: 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Estimated Two Year Progression Free Survival Rate for All Participants | 64 percentage of participants |
Secondary
Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants
Time frame: 2 years after allogeneic transplant
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Estimated Two Year Progression Free Survival Rate for Participants Undergoing Both Autologous and Allogeneic Transplants | 72 percentage of participants |
Secondary
Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant
Time frame: Two Years
Population: Participants who ONLY underwent Autologous transplant (did not proceed to Allogeneic)
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Estimated Two Year Progression Free Survival Rate for Participants Undergoing Only Autologous Transplant | 46 percentage of participants |
Secondary
Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL
Time frame: within 28 days after allogeneic transplant
Population: This was only measured in the 17 participants who experienced a hematological nadir after allo transplant.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Autologous Then Allogeneic Transplant | Number of Days After Allogeneic Transplant Until Absolute Neutrophil Count Was Equal to or Greater Than 500/uL | 12 days |